SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-174475"
 

Search: onr:"swepub:oai:DiVA.org:liu-174475" > Higher vs Lower Dos...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007502naa a2200877 4500
001oai:DiVA.org:liu-174475
003SwePub
008210321s2021 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:146058114
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1744752 URI
0247 a https://doi.org/10.1111/aas.137932 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1460581142 URI
040 a (SwePub)liud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Granholm, Andersu Univ Copenhagen, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut
2451 0a Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysis
264 c 2021-02-25
264 1b WILEY,c 2021
338 a print2 rdacarrier
500 a Funding Agencies|Novo Nordisk FoundationNovo Nordisk Foundation [0062998]; Rigshospitalets Research Council [E-22703-06]
520 a Background Coronavirus disease 2019 (COVID-19) can lead to severe hypoxic respiratory failure and death. Corticosteroids decrease mortality in severely or critically ill patients with COVID-19. However, the optimal dose remains unresolved. The ongoing randomised COVID STEROID 2 trial investigates the effects of higher vs lower doses of dexamethasone (12 vs 6 mg intravenously daily for up to 10 days) in 1,000 adult patients with COVID-19 and severe hypoxia. Methods This protocol outlines the rationale and statistical methods for a secondary, pre-planned Bayesian analysis of the primary outcome (days alive without life support at day 28) and all secondary outcomes registered up to day 90. We will use hurdle-negative binomial models to estimate the mean number of days alive without life support in each group and present results as mean differences and incidence rate ratios with 95% credibility intervals (CrIs). Additional count outcomes will be analysed similarly and binary outcomes will be analysed using logistic regression models with results presented as probabilities, relative risks and risk differences with 95% CrIs. We will present probabilities of any benefit/harm, clinically important benefit/harm and probabilities of effects smaller than pre-defined clinically minimally important differences for all outcomes analysed. Analyses will be adjusted for stratification variables and conducted using weakly informative priors supplemented by sensitivity analyses using sceptic priors. Discussion This secondary, pre-planned Bayesian analysis will supplement the primary, conventional analysis and may help clinicians, researchers and policymakers interpret the results of the COVID STEROID 2 trial while avoiding arbitrarily dichotomised interpretations of the results. Trial registration ClinicalTrials.gov: NCT04509973; EudraCT: 2020-003363-25.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
7001 a Munch, Marie Warreru Univ Copenhagen, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut
7001 a Myatra, Sheila Nainanu Tata Mem Hosp, India4 aut
7001 a Vijayaraghavan, Bharath Kumar Tirupakuzhiu Apollo Hosp, India; Chennai Crit Care Consultants, India; Univ New South Wales, India4 aut
7001 a Cronhjort, Mariau Karolinska Institutet,Karolinska Inst, Sweden4 aut
7001 a Wahlin, Rebecka Rubensonu Karolinska Institutet,Karolinska Inst, Sweden4 aut
7001 a Jakob, Stephan M.u Univ Bern, Switzerland4 aut
7001 a Cioccari, Lucau Univ Bern, Switzerland4 aut
7001 a Kjaer, Maj-Brit Norregaardu Univ Copenhagen, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut
7001 a Vesterlund, Gitte Kingou Univ Copenhagen, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut
7001 a Meyhoff, Tine Sylvestu Univ Copenhagen, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut
7001 a Helleberg, Marieu Univ Copenhagen, Denmark4 aut
7001 a Moller, Morten Hylanderu Univ Copenhagen, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut
7001 a Benfield, Thomasu Copenhagen Univ Hosp Amager & Hvidovre, Denmark4 aut
7001 a Venkatesh, Balasubramanianu Univ New South Wales, Australia4 aut
7001 a Hammond, Naomiu Univ New South Wales, Australia4 aut
7001 a Chew, Michelle S,d 1969-u Linköpings universitet,Medicinska fakulteten,Avdelningen för klinisk kemi och farmakologi,Region Östergötland, ANOPIVA US4 aut0 (Swepub:liu)micch61
7001 a Bassi, Abhinavu Univ New South Wales, India4 aut
7001 a John, Oommenu Univ New South Wales, India; Manipal Acad Higher Educ, India4 aut
7001 a Jha, Vivekanandu Univ New South Wales, India; Manipal Acad Higher Educ, India; Imperial Coll London, England4 aut
7001 a Kristiansen, Klaus Tjelleu Univ Copenhagen, Denmark4 aut
7001 a Ulrik, Charlotte Suppliu Univ Copenhagen, Denmark4 aut
7001 a Lind Jorgensen, Vibekeu Univ Copenhagen, Denmark4 aut
7001 a Smitt, Margitu Univ Copenhagen, Denmark4 aut
7001 a Bestle, Morten H.u Copenhagen Univ Hosp, Denmark; Univ Copenhagen, Denmark4 aut
7001 a Andreasen, Anne Sofieu Univ Copenhagen, Denmark4 aut
7001 a Poulsen, Lone Musaeusu Zealand Univ Hosp, Denmark4 aut
7001 a Rasmussen, Bodil Steenu Collaborat Res Intens Care CRIC, Denmark; Aalborg Univ Hosp, Denmark4 aut
7001 a Brochner, Anne Craveirou Kolding Cty Hosp, Denmark4 aut
7001 a Strom, Thomasu Odense Univ Hosp, Denmark; Univ Hosp Southern Denmark, Denmark4 aut
7001 a Moller, Andersu Naestved Slagelse Ringsted Hosp, Denmark4 aut
7001 a Khan, Mohd Saifu Rajendra Inst Med Sci, India4 aut
7001 a Padmanaban, Ajayu Apollo Hosp, India4 aut
7001 a Divatia, Jigeeshu Vasishthau Tata Mem Hosp, India4 aut
7001 a Saseedharan, Sanjithu SL Raheja Hosp, India4 aut
7001 a Borawake, Kapilu Vishwaraj Hosp, India4 aut
7001 a Kapadia, Farhadu Hinduja Hosp, India4 aut
7001 a Dixit, Subhalu Sanjeevan Hosp, India4 aut
7001 a Chawla, Rajeshu Indraprastha Apollo Hosp, India4 aut
7001 a Shukla, Urviu Symbiosis Univ Hosp & Res Ctr, India4 aut
7001 a Amin, Pravinu Bombay Hosp Inst Med Sci, India4 aut
7001 a Chew, Michelle S,d 1969-u Linköpings universitet,Medicinska fakulteten,Avdelningen för klinisk kemi och farmakologi,Region Östergötland, ANOPIVA US4 aut0 (Swepub:liu)micch61
7001 a Gluud, Christianu Copenhagen Univ Hosp, Denmark4 aut
7001 a Lange, Theisu Univ Copenhagen, Denmark4 aut
7001 a Perner, Andersu Univ Copenhagen, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut
7102 a Univ Copenhagen, Denmark; Collaborat Res Intens Care CRIC, Denmarkb Tata Mem Hosp, India4 org
7730 t Acta Anaesthesiologica Scandinavicad : WILEYg 65:5, s. 702-710q 65:5<702-710x 0001-5172x 1399-6576
8564 u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/aas.13793
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-174475
8564 8u https://doi.org/10.1111/aas.13793
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:146058114

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view